## /2Benefect

## Ebola Outbreak Comes To North America

Ontario, CA - October 3 - Ebola is a contagious deadly disease found primarily in Africa but is not expected to be a significant public threat in North America where hygiene standards \& health care systems are more advanced. The Ebola virus is an Enveloped Virus which is transmitted through direct contact with infected blood or body fluids/substances.

However, although Benefect nor any other disinfectant has been specifically tested against Ebola, based on the CDC disinfectant recommendations per Ebola \& their rankings of disinfectant potency (below), Benefect is a Intermediate-Level Tuberculocidal disinfectant which is considerably more potent than what is normally required for an enveloped virus such as Ebola.

Additionally, Benefect Broad Spectrum Disinfectant has efficacy against similarly classified enveloped viruses such as HIV \& Decon 30 has efficacy against similarly classified Influenza, H1N1 \& non-enveloped viruses such as Rotavirus.


The CDC specifically states that "although there are no products with specific label claims against the Ebola virus, enveloped viruses such as Ebola are susceptible to a broad range of hospital disinfectants used to disinfect hard, non-porous surfaces. In contrast, non-enveloped viruses are more resistant to disinfectants. As a precaution, selection of a disinfectant product with a higher potency than what is normally required for an enveloped virus is being recommended at this time."

The EPA has not released any official guidance regarding Ebola claims for EPA Registered Disinfectant Manufacturers as of the date of this bulletin. Although we are assured that the EPA is working 24/7 reviewing their standards to come up with a surrogate claim for the marketplace during this time as they have done for H1N1 \& SARS in the past.

Resources:
Centre for Disease Control and Prevention http://www.cdc.gov/vhf/ebola/

